These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

516 related items for PubMed ID: 26608564

  • 1. Serum tenascin-C discriminates patients with active SLE from inactive patients and healthy controls and predicts the need to escalate immunosuppressive therapy: a cohort study.
    Závada J, Uher M, Svobodová R, Olejárová M, Hušáková M, Ciferská H, Hulejová H, Tomčík M, Šenolt L, Vencovský J.
    Arthritis Res Ther; 2015 Nov 25; 17():341. PubMed ID: 26608564
    [Abstract] [Full Text] [Related]

  • 2. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.
    Petri MA, van Vollenhoven RF, Buyon J, Levy RA, Navarra SV, Cervera R, Zhong ZJ, Freimuth WW, BLISS-52 and BLISS-76 Study Groups.
    Arthritis Rheum; 2013 Aug 25; 65(8):2143-53. PubMed ID: 23754628
    [Abstract] [Full Text] [Related]

  • 3. Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus.
    Ho A, Magder LS, Barr SG, Petri M.
    Arthritis Rheum; 2001 Oct 25; 44(10):2342-9. PubMed ID: 11665975
    [Abstract] [Full Text] [Related]

  • 4. A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus.
    Ho A, Barr SG, Magder LS, Petri M.
    Arthritis Rheum; 2001 Oct 25; 44(10):2350-7. PubMed ID: 11665976
    [Abstract] [Full Text] [Related]

  • 5. A surge in anti-dsDNA titer predicts a severe lupus flare within six months.
    Pan N, Amigues I, Lyman S, Duculan R, Aziz F, Crow MK, Kirou KA.
    Lupus; 2014 Mar 25; 23(3):293-8. PubMed ID: 24316605
    [Abstract] [Full Text] [Related]

  • 6. Disease activity patterns in a monocentric cohort of SLE patients: a seven-year follow-up study.
    Zen M, Bassi N, Nalotto L, Canova M, Bettio S, Gatto M, Ghirardello A, Iaccarino L, Punzi L, Doria A.
    Clin Exp Rheumatol; 2012 Mar 25; 30(6):856-63. PubMed ID: 22765883
    [Abstract] [Full Text] [Related]

  • 7. Serum DNase I activity in systemic lupus erythematosus: correlation with immunoserological markers, the disease activity and organ involvement.
    Skiljevic D, Jeremic I, Nikolic M, Andrejevic S, Sefik-Bukilica M, Stojimirovic B, Bonaci-Nikolic B.
    Clin Chem Lab Med; 2013 May 25; 51(5):1083-91. PubMed ID: 23183758
    [Abstract] [Full Text] [Related]

  • 8. Circulating anti-double-stranded DNA antibody-secreting cells in patients with systemic lupus erythematosus: a novel biomarker for disease activity.
    Hanaoka H, Okazaki Y, Satoh T, Kaneko Y, Yasuoka H, Seta N, Kuwana M.
    Lupus; 2012 Oct 25; 21(12):1284-93. PubMed ID: 22740429
    [Abstract] [Full Text] [Related]

  • 9. British Isles Lupus Assessment Group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus.
    Yee CS, Farewell V, Isenberg DA, Rahman A, Teh LS, Griffiths B, Bruce IN, Ahmad Y, Prabu A, Akil M, McHugh N, D'Cruz D, Khamashta MA, Maddison P, Gordon C.
    Arthritis Rheum; 2007 Dec 25; 56(12):4113-9. PubMed ID: 18050213
    [Abstract] [Full Text] [Related]

  • 10. Association of antinucleosome antibodies with disease flare in serologically active clinically quiescent patients with systemic lupus erythematosus.
    Ng KP, Manson JJ, Rahman A, Isenberg DA.
    Arthritis Rheum; 2006 Dec 15; 55(6):900-4. PubMed ID: 17139667
    [Abstract] [Full Text] [Related]

  • 11. Subclinical disease activity in systemic lupus erythematosus: immunoinflammatory markers do not normalize in clinical remission.
    Wais T, Fierz W, Stoll T, Villiger PM.
    J Rheumatol; 2003 Oct 15; 30(10):2133-9. PubMed ID: 14528506
    [Abstract] [Full Text] [Related]

  • 12. Serum free light chains as biomarkers for systemic lupus erythematosus disease activity.
    Aggarwal R, Sequeira W, Kokebie R, Mikolaitis RA, Fogg L, Finnegan A, Plaas A, Block JA, Jolly M.
    Arthritis Care Res (Hoboken); 2011 Jun 15; 63(6):891-8. PubMed ID: 21312346
    [Abstract] [Full Text] [Related]

  • 13. Elevated BLyS levels in patients with systemic lupus erythematosus: Associated factors and responses to belimumab.
    Roth DA, Thompson A, Tang Y, Hammer AE, Molta CT, Gordon D.
    Lupus; 2016 Apr 15; 25(4):346-54. PubMed ID: 26385220
    [Abstract] [Full Text] [Related]

  • 14. Prior anti-dsDNA antibody status does not predict later disease manifestations in systemic lupus erythematosus.
    van den Berg L, Nossent H, Rekvig O.
    Clin Rheumatol; 2006 May 15; 25(3):347-52. PubMed ID: 16328091
    [Abstract] [Full Text] [Related]

  • 15. The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial.
    Tseng CE, Buyon JP, Kim M, Belmont HM, Mackay M, Diamond B, Marder G, Rosenthal P, Haines K, Ilie V, Abramson SB.
    Arthritis Rheum; 2006 Nov 15; 54(11):3623-32. PubMed ID: 17075807
    [Abstract] [Full Text] [Related]

  • 16. Urine neopterin as a parameter of disease activity in patients with systemic lupus erythematosus: comparisons with serum sIL-2R and antibodies to dsDNA, erythrocyte sedimentation rate, and plasma C3, C4, and C3 degradation products.
    Lim KL, Jones AC, Brown NS, Powell RJ.
    Ann Rheum Dis; 1993 Jun 15; 52(6):429-35. PubMed ID: 8323394
    [Abstract] [Full Text] [Related]

  • 17. Serum and urine interleukin-17A levels as biomarkers of disease activity in systemic lupus erythematosus.
    Nordin F, Shaharir SS, Abdul Wahab A, Mustafar R, Abdul Gafor AH, Mohamed Said MS, Rajalingham S, Shah SA.
    Int J Rheum Dis; 2019 Aug 15; 22(8):1419-1426. PubMed ID: 31179646
    [Abstract] [Full Text] [Related]

  • 18. The effect of methotrexate on improving serological abnormalities of patients with systemic lupus erythematosus.
    Miyawaki S, Nishiyama S, Aita T, Yoshinaga Y.
    Mod Rheumatol; 2013 Jul 15; 23(4):659-66. PubMed ID: 23011357
    [Abstract] [Full Text] [Related]

  • 19. Identification of clinical predictors of flare in systemic lupus erythematosus patients: a 24-month prospective cohort study.
    Inês L, Duarte C, Silva RS, Teixeira AS, Fonseca FP, da Silva JA.
    Rheumatology (Oxford); 2014 Jan 15; 53(1):85-9. PubMed ID: 24067885
    [Abstract] [Full Text] [Related]

  • 20. Hyperprolactinemia in males with systemic lupus erythematosus.
    Mok CC, Lau CS, Lee KW, Wong RW.
    J Rheumatol; 1998 Dec 15; 25(12):2357-63. PubMed ID: 9858430
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.